The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1535
Naldemedine (Symproic) for Opioid-Induced Constipation
The full article is available to subscribers Subscriber Login   

The FDA has approved the opioid receptor antagonist naldemedine (Symproic – Shionogi) for treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain. Naldemedine is the third oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved for this indication; naloxegol (Movantik) and methylnaltrexone (Relistor) were approved earlier.

STANDARD TREATMENT – Laxatives and stool softeners are commonly used, often in combination, for initial treatment of OIC, but their efficacy is limited. Lubiprostone (Amitiza), an oral chloride channel activator, has been shown to increase the frequency of bowel movements in patients with chronic noncancer pain and OIC.1 Oral methylnaltrexone and naloxegol appear to be more effective than lubiprostone, and subcutaneous methylnaltrexone appears to be more effective than any ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Naldemedine (Symproic) for Opioid-Induced Constipation
Article code: 1535b
 Electronic, downloadable article - $25